The Highland Breast Care Center announced today they are now offering patients with early stage breast cancer a new treatment called MammoSite Radiation Therapy. MammoSite delivers radiation directly to the tissue surrounding the original tumor, minimizing radiation exposure to healthy tissue and reducing the length of treatment from five to seven weeks to one to five days. The MammoSite device is a balloon catheter that is inserted into the cavity created by a lumpectomy the surgical removal of a breast tumor.
We have updated our approval process of Consensus Statements. The senior author will need to provide a list of publications and is required to have published on the topic of interest in the last 5 years. All proposed ABS consensus statements will include a summary paragraph detailing the subject matter and timeline.
High Dose Rate HDR brachytherapy is a type of radiation that is delivered inside the body via implants placed close to or inside the cancerous tumor. The entire course of treatment can take as little one day. With HDR, small hollow catheters are inserted into the tumor.
Study record managers: refer to the Data Element Definitions if submitting registration or results information. The MammoSite applicator is inserted into the cavity created by the tumor removal surgery. The MammoSite applicator is then inflated and expands to fill the cavity.
When a breast tumor is large or not easily removed by surgeryradiation therapy before surgery may help to shrink the breast tumor. After breast-sparing surgery, radiation treatments may help destroy remaining breast cancer cells. Potential advantages of AccuBoost for breast cancer include:.
Brachytherapy places radioactive sources internally very close to the area to be treated. Needle or balloon implants are placed in the operating room, but treatments occur on an outpatient basis. The temporary implants do not cause the patient to be radioactive and are removed after a series of twice-daily treatments.
The purpose of this study was to report the treatment-induced adverse events and cosmetic and treatment outcomes of accelerated partial breast irradiation APBI delivered with the MammoSite radiation therapy system RTS in breast cancer patients undergoing breast-conserving therapy BCT. This is a prospective clinical trial that was approved by the institutional review board. The study included 36 eligible patients treated consecutively in our institution between November and August
The multi-lumen catheter has four offset lumens to allow for dosimetric optimization to minimize skin dose. Brachytherapy Brochure. Professional Medical Society Treatment Guidelines.
Using minute 'seeds' doctors can target the treatment much more effectively and a shorter course of treatment means women suffer the side effects such as nausea and fatigue for a more limited period. Standard treatment for early stage breast cancer typically involves a course of radiotherapy after the tumour has been removed through surgery to ensure any remaining cancer cells are killed. Traditional radiotherapy exposes the whole area to radiation but a new evolving technique, called Accelerated partial breast irradiation APBI using ballon brachytherapy mean tiny radioactive seeds can be injected into the area from where the tumour was removed to treat a smaller area of tissue.
This report presents the 5-year results of the treated patients. Forty-three patients completed accelerated partial breast irradiation with MammoSite brachytherapy following lumpectomy and axillary staging. Thirty-six patients have been followed for a median of 5. A minimum balloon-to-skin surface distance of 5 mm was required.